Back to Agenda
Session 2: How Can JSCs Support Better Evidence Generation? (Roundtable Discussions)
Session Chair(s)
Claudine Sapède, PharmD
Director, Global HTA Policy
NOVARTIS INTERNATIONAL, Switzerland
In this session, stakeholders will share their views on opportunities and challenges with JSCs. Afterwards and through roundtable discussions, participants will be able to hear first-hand from the other stakeholders and will be invited to provide input to the topics being discussed:
Roundtable 1: Patients and HCPs involvement in JSC (and JCA) processes - Challenges and opportunities for strong stakeholder involvement.
Roundtable 2: What would “good” look like for JSCs in the interim period and post 2025?
Roundtable 3: Generating better RWE for HTA
Speaker(s)
Setting the Scene
Michael Berntgen, PhD
European Medicines Agency, Netherlands
Head of Scientific Evidence Generation
Setting the Scene
Julien Delaye
EURORDIS, France
Patient Engagement Manager - HTA
Setting the Scene
Claudine Sapède, PharmD
NOVARTIS INTERNATIONAL, Switzerland
Director, Global HTA Policy
Setting the Scene
Stephanie Said
Federal Joint Committee/Gemeinsamer Bundesausschuss (G-BA), Germany
Scientific Advisor and Chair of the HTA Coordination Group Subgroup on JSC
Have an account?